Skip to main content

Table 4 Comparison of genetic variants and other risk factors in patients with different grades of hepatic steatosis after liver transplantation

From: Variations in TM6SF2, PCSK9 and PCSK7 genes and risk of hepatic steatosis after liver transplantation: a cross-sectional study

Univariate Multivariate analysis
  Moderate to severe steatosis Mild steatosis P value OR 95% CI P value
Age (year) 51.90 ± 9.94 47.41 ± 11.27 0.207    
Sex (male/female) 10/10 13/4 0.098    
Height (cm) 167.10 ± 11.55 169.41 ± 9.23 0.511    
Weight (kg) 86 ± 16.89 74.76 ± 16.47 0.049    
BMI (kg/m2) 30.81 ± 5.11 25.99 ± 5.38 0.008 1.055 0.855–1.301 0.620
WC (cm) 109.74 ± 11.74 99.29 ± 9.95 0.006 1.062 0.953–1.183 0.276
AST (IU/L) 21.62 ± 9.4 23.92 ± 13.61 0.590    
ALT (IU/L) 24.43 ± 11.76 26.57 ± 13.74 0.650    
PTDM 57.9% 64.7% 0.676    
Post-transplant HLP 47.4% 47.1% 0.985    
Post-transplant HTN 42.1% 35.3% 0.676    
Rejection 36.7% 34.5% 0.839    
Mean prednisolone dose (mg) 8.26 ± 3.87 7.20 ± 3.74 0.379    
TM6SF2 genotype
 CT + TT versus CC 75% 76.5% 0.917    
PCSK9 genotype
 AG + GG versus AA 65% 17.6% 0.004 5.747 1.086–30.303 0.040
PCSK7 genotype
 CT + TT versus CC 65% 88.2% 0.101    
  1. BMI body mass index, AST aspartate aminotransferase, ALT alanine aminotransferase, PTDM post-transplant diabetes mellitus, HLP hyperlipidemia, HTN hypertension, WC waist circumference, HC hip circumference, TM6SF2 transmembrane 6 super family 2, PCSK9 proprotein convertase subtilisin/kexin type 9, PCSK7 proprotein convertase subtilisin/kexin type 7